肿瘤细胞治疗研究
ALL SOURCES
Recurrence score prediction formula based on immunohistochemistry and biopsy data to predict response to neoadjuvant chemotherapy in estrogen receptor
在61例患者中（中位年龄54岁），50%的患者临床肿瘤状态为2个肿瘤，40%的患者为淋巴结阳性疾病。
Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Ch
NLR 可能是接受新辅助 pembrolizumab 联合化疗的 TNBC 患者 pCR 的一个简单易得的预测指标。将外周血免疫标志物与瘤内免疫参数相结合，可能有助于改进治疗分层。
Roles of Tumor-Infiltrating Lymphocytes and Antitumor Immune Responses as Predictive and Prognostic Markers in Patients with Breast Cancer Receiving N
TIL（肿瘤浸润淋巴细胞）(TILs) 被认为在接受新辅助化疗 (NAC) 的乳腺癌患者的肿瘤缩小和生存延长中发挥重要作用。
Changes in CD8-positive lymphocytes following chemotherapy with concomitant bevacizumab in HER2-negative breast cancer.
含贝伐珠单抗的化疗似乎可增强原发乳腺肿瘤中 CD8 阳性 TIL 的浸润，这可能有助于改善局部肿瘤消退和更好的治疗结局。
Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.
HER2-low与HER2-zero TNBC是生物学上不同的亚组。HER2-low肿瘤富集luminal AR样特征，而HER2-zero肿瘤表现出basal-like、高度增殖和免疫原性特征。尽管治疗结局无显著差异，这些发现提示HER2-low与HER2-zero TNBC可能需要不同的治疗策略。有必要开展前瞻性研究以验证这些发现并进一步探索个体化治疗策略。
Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.
曲妥珠单抗作为 HER2 阳性 AGC 的标准治疗已长达十年，随后，抗体偶联药物（ADC）德曲妥珠单抗问世，并展现出令人瞩目的缓解。
Anti-HER2 Cancer-Specific mAb, H(2)Mab-250-hG(1), Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab.
这些结果表明，ADCC和CDC活性对H 2 Mab-250-hG 1和trastuzumab的抗肿瘤效果有不同的贡献，并为H 2 Mab-250-hG 1针对HER2阳性肿瘤的临床开发指明了未来方向。
Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms.
胆管癌（CCA）是一种侵袭性强且致命的癌症。
The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
约 30% 的骨肉瘤患者存在 HER2 过表达，针对骨肉瘤的 HER2 靶向治疗以及 HER2 的预后和/或预测价值也已被研究。
Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells.
腺病毒-REIC/Dkk-3表达载体（Ad-REIC）因其在癌症淬灭方面的潜力，已成为众多临床研究的焦点。
MEMBER ACCOUNT
登录成功会直接打开下一页。
